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Abstract
Medical researchers are coming to appreciate that many diseases are in fact com-
plex, heterogeneous syndromes composed of subpopulations that express different
variants of a related complication. Time series data extracted from individual elec-
tronic health records (EHR) offer an exciting new way to study subtle differences
in the way these diseases progress over time. In this paper, we focus on answering
two questions that can be asked using these databases of time series. First, we want
to understand whether there are individuals with similar disease trajectories and
whether there are a small number of degrees of freedom that account for differ-
ences in trajectories across the population. Second, we want to understand how
important clinical outcomes are associated with disease trajectories. To answer
these questions, we propose the Disease Trajectory Map (DTM), a novel proba-
bilistic model that learns low-dimensional representations of sparse and irregularly
sampled time series. We propose a stochastic variational inference algorithm for
learning the DTM that allows the model to scale to large modern medical datasets.
To demonstrate the DTM, we analyze data collected on patients with the complex
autoimmune disease, scleroderma. We find that DTM learns meaningful represen-
tations of disease trajectories that the representations are significantly associated
with important clinical outcomes.
1 Introduction
Time series data is becoming increasingly important in medical research and practice. This is due,
in part, to the growing adoption of electronic health records (EHRs), which capture snapshots of
an individual’s state over time. These snapshots include clinical observations (apparent symptoms
and vital sign measurements), laboratory test results, and treatment information. In parallel, medical
researchers are beginning to recognize and appreciate that many diseases are in fact complex, highly
heterogeneous syndromes [Craig, 2008] and that individuals may belong to disease subpopulations
or subtypes that express similar sets of symptoms over time (see e.g. Saria and Goldenberg [2015]).
Examples of such diseases include asthma [Lötvall et al., 2011], autism [Wiggins et al., 2012], and
COPD [Castaldi et al., 2014]. The data captured in EHRs can help better understand these complex
diseases. EHRs contain a multitude of types of observations and the ability to track their progression
can help bring in to focus the subtle differences across individual disease expression.
In this paper, we focus on two exploratory questions that we can begin to answer using repositories
of biomedical time series data. First, we want to discover whether there are individuals with similar
disease trajectories and whether there are a small number of degrees of freedom that account for
differences across a heterogeneous population. A better understanding of the types of trajectories
and how they differ can yield insights into the biological underpinnings of the disease. In turn, this
may motivate new targeted therapies. In the clinic, physicians can analyze an individual’s clinical
history to better understand the “flavor” of the disease being expressed and can use this knowledge
to make more accurate prognoses and guide treatment decisions. Second, we would like to know
whether individuals with similar clinical outcomes (e.g. death, severe organ damage, or development
of comorbidities) have similar disease trajectories. In complex diseases, individuals are often at
risk of developing a number of severe complications and clinicians rarely have access to accurate
prognostic biomarkers. Discovering associations between target outcomes and trajectory patterns
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may both generate new hypotheses regarding the causes of these outcomes and help clinicians to
better anticipate the event using an individual’s clinical history.
Contributions. Our approach to simultaneously answering these questions is to embed individual
disease trajectories into a low-dimensional vector space wherein similarity in the embedded space
implies that two individuals have similar trajectories. Such an embedding would naturally answer our
first question, and the results could also be used to answer the second by comparing distributions
over embeddings across groups defined by different outcomes. To produce such an embedding, we
introduce a novel probabilistic model of biomedical time series data, which we term the Disease
Trajectory Map (DTM). In particular, the DTM models the trajectory of a single clinical marker,
which is an observation or measurement recorded over time by clinicians that are used to track
the progression of a disease (see e.g. Schulam et al. [2015]). Examples of clinical markers are
pulmonary function tests or creatinine laboratory test results, which track lung and kidney function
respectively. The DTM discovers low-dimensional (2D or 3D) latent representations of clinical
marker trajectories that are easy to visualize. Moreover, the model learns an expressive family of
distributions over trajectories that is parameterized by the low-dimensional representation. This
allows the DTM to capture a wide variety of trajectory shapes, making it suitable for studying
complex diseases where expression varies widely across the population. We describe a stochastic
variational inference algorithm for estimating the posterior distribution over the parameters and
individual-specific representations, which allows our model to be easily applied to large biomedical
datasets. To demonstrate the DTM, we analyze clinical marker data collected on individuals with the
complex autoimmune disease scleroderma (see e.g. Allanore et al. [2015]). We find that the learned
representations capture interesting subpopulations consistent with previous findings, and that the
representations suggest associations with important clinical outcomes.
1.1 Background and Related Work
Clinical marker data extracted from EHRs is a by-product of an individual’s interactions with the
healthcare system. As a result, the time series are often irregularly sampled (the time between
samples varies within and across individuals), and may be extremely sparse (it is not unusual to
have a single observation for an individual). To aid the following discussion, we briefly introduce
notation for this type of data. We use m to denote the number of individual disease trajectories
recorded in a given dataset. For each individual, we use ni to denote the number of observations.
We collect the observation times for subject i into a column vector ti (sorted in non-decreasing
order) and the corresponding measurements into a column vector yi: ti , [ti1, . . . , tini ]> and
yi , [yi1, . . . , yini ]>. Our goal is to embed the pair (ti,yi) into a low-dimensional vector space
wherein similarity between two embeddings (xi,xj) implies that the trajectories have similar shapes.
This is commonly done using basis representations of the trajectories.
Fixed basis representations. In the statistics literature, trajectory data is often referred to as
unbalanced longitudinal data, and it is commonly analyzed in that community using linear mixed
models (LMMs) [Verbeke and Molenberghs, 2009]. In their simplest form, LMMs assume the
following probabilistic model:
wi | Σ ∼ N (0,Σ) , yi | Bi,wi, µ, σ2 ∼ N (µ+ Biwi, σ2Ini). (1)
The matrix Bi ∈ Rni×d is known as the design matrix, and can be used to capture non-linear
relationships between the observation times ti and measurements yi. Its rows are comprised of
d-dimensional basis expansions of each observation time Bi = [b(ti1), · · · ,b(tini)]>. Common
choices of b(·) include polynomials, splines, wavelets, and Fourier series. The particular basis
used is often carefully crafted by the analyst depending on the nature of the trajectories and on
the desired structure (e.g. invariance to translations and scaling) in the representation [Brillinger,
2001]. The design matrix can therefore make the LMM remarkably flexible despite its simple
parametric probabilistic assumptions. Moreover, the prior over wi and the conjugate likelihood make
it straightforward to fit µ, Σ, and σ2 using EM or Bayesian posterior inference.
After estimating the model parameters, we can estimate the coefficients wi of a given clinical marker
trajectory using the posterior distribution, which embeds the trajectory in a Euclidean space. To
flexibly capture complex trajectory shapes, however, the basis must be high-dimensional, which
makes interpretability of the embeddings challenging. We can use low-dimensional summaries such
as the projection on to a principal subspace, but these are not necessarily substantively meaningful.
Indeed, much research has gone into developing principal direction post-processing techniques (e.g.
Kaiser [1958]) or alternative estimators that enhance interpretability (e.g. Carvalho et al. [2012]).
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Data-adaptive basis representations. A set of related, but more flexible, techniques comes from
functional data analysis where observations are functions (i.e. trajectories) assumed to be sampled
from a stochastic process and the goal is to find a parsimonious representation for the data [Ramsay
et al., 2002]. Functional principal component analysis (FPCA), one of the most standard techniques in
functional data analysis, expresses functional data in the orthonormal basis given by the eigenfunctions
of the auto-covariance operator. This representation is optimal in the sense that no other representation
captures more variation [Ramsay, 2006]. The idea itself can be traced back to early independent
work by Karhunen and Loeve and is also referred to as the Karhunen-Loeve expansion [Watanabe,
1965]. While numerous variants of FPCA have been proposed, the one that is most relevant to the
problem at hand is that of sparse FPCA [Castro et al., 1986, Rice and Wu, 2001] where we allow
sparse irregularly sampled data as in longitudinal data analysis. To deal with the sparsity, Rice and
Wu [2001] proposed the mixed effect model which leverages statistical strength from all observations
for function estimation. The mixed effect model often suffers from numerical instability of covariance
matrices in high dimensions; James et al. [2000] addressed this by constraining the rank of the
covariance matrices—this is often referred to as the reduced rank model. The reduced rank model
was further extended by Zhou et al. [2008] to a two-dimensional sparse principal component model.
Although the reduced rank model embeds trajectories using a data-driven basis, the basis is restricted
to lie in a linear subspace of a fixed basis, which may be overly restrictive. Other approaches to
learning a functional basis include Bayesian estimation of B-spline parameters (e.g. [Bigelow and
Dunson, 2012]) and placing priors over reproducing kernel Hilbert spaces (e.g. [MacLehose and
Dunson, 2009]). Although flexible, these two approaches do not learn a compact representation.
Cluster-based representations. Mixture models and clustering approaches are also commonly
used to represent and discover structure in time series data. Marlin et al. [2012] cluster time series
data from the ICU using a mixture model and use cluster membership to predict outcomes. Schulam
and Saria [2015] describe a probabilistic model that represents trajectories using a hierarchy of
features, which includes “subtype” or cluster membership. LMMs have also been extended to have
nonparametric Dirichlet process priors over the coefficients (e.g. Kleinman and Ibrahim [1998]),
which implicitly induce clusters in the data. Although these approaches flexibly model trajectory
data, the structure they recover is a partition, which does not allow us to compare all trajectories in a
coherent way as we can in a vector space.
Lexicon-based representations. Another line of research has investigated the discovery of motifs
or repeated patterns in continuous time-series data for the purposes of succinctly representing the
data as a string of elements of the discovered lexicon. These include efforts in the speech processing
community to identify sub-word units (parts of the words at the same level as phonemes) in a data-
driven manner [Varadarajan et al., 2008, Levin et al., 2013]. In computational healthcare, Saria et al.
[2011] propose a method for discovering deformable motifs that are repeated in continuous time-series
data. These methods are, in spirit, similar to discretization approaches such as symbolic aggregate
approximation (SAX) [Lin et al., 2007] and piecewise aggregate approximation (PAX) [Keogh et al.,
2001] that are popular in data mining, and aim to find compact description of sequential data, primarily
for the purposes of indexing, search, anomaly detection, and information retrieval. The focus in this
paper is to learn representations for entire trajectories rather than discover a lexicon. Furthermore, we
are interested in learning a representation for individuals and capturing latent similarities between
two patients in terms of Euclidean distances in the learnt representation.
2 Disease Trajectory Maps
To motivate Disease Trajectory Maps, we begin from the reduced-rank formulation of linear mixed
models as proposed by James et al. [2000]. In particular, let µ ∈ R be the marginal mean of the
observations, F ∈ Rd×q be a rank-q matrix, and σ2 be the variance of measurement errors. As a
reminder, yi ∈ Rni denotes the vector of observed trajectory measurements, Bi ∈ Rni×d denotes
the subject’s design matrix, and xi ∈ Rq denotes the representation or embedding of the subject. We
begin with the reduced-rank conditional model: yi | Bi,xi, µ,F, σ2 ∼ N (µ + BiFxi, σ2Ini). In
the reduced-rank model, we assume an isotropic normal prior over xi and marginalize to obtain the
observed-data log-likelihood, which is then optimized with respect to F. Here, just as was done by
Lawrence [2004] to derive the GPLVM, we swap the marginalization for optimization and vice versa.
By assuming a normal prior N (0, αIk) over the rows of F and marginalizing we obtain:
yi | Bi,xi, µ, σ2, α ∼ N (µ, α〈xi,xi〉BiB>i + σ2Ini). (2)
Note that by marginalizing over F, we induce a joint distribution over all trajectories in the dataset.
Moreover, this joint distribution is a Gaussian process with mean µ and the following covariance
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function defined across trajectories:
Cov(yi,yj | Bi,Bj ,xi,xj , µ, σ2, α) = α〈xi,xj〉BiB>j + I[i = j] (σ2Ini). (3)
This reformulation of the reduced-rank LMM suggests a natural alternative to learning the repre-
sentations xi of the subjects. Just as in the GPLVM, we can maximize the log-probability of all
trajectories with respect to the hyperparameters {µ, σ2, α} and the representations {xi : i ∈ [m]}.
More importantly, however, the reformulation allows us to relate the representation to the basis
coefficients non-linearly by using the “kernel trick” to reparameterize the covariance function. Let
k(·, ·) denote a non-linear kernel defined over the representations with parameters θ, then we have:
Cov(yi,yj | Bi,Bj ,xi,xj , µ, σ2,θ) = k(xi,xj)BiB>j + I[i = j] (σ2Ini). (4)
Let y , [y>1 , . . . ,y>m]> denote the column vector obtained by concatenating the measurement
vectors from each trajectory. The joint distribution over y is a multivariate normal:
y | B1:m,x1:m, µ, σ2,θ ∼ N (µ,ΣDTM + σ2In), (5)
where ΣDTM is a full-rank covariance matrix that depends on the design matrices B1:m, the repre-
sentations x1:m, and the kernel k(·, ·). In particular, ΣDTM is a block-structured matrix with m row
blocks and m column blocks. The block at the ith row and jth column is the covariance between yi
and yj defined above. We complete the model by placing isotropic Gaussian priors over xi. Note that
this model is similar to the Bayesian GPLVM [Titsias and Lawrence, 2010], but models functional
data instead of finite-dimensional vectors.
2.1 Learning and Inference in the DTM
As formulated, the model will scale poorly to large datasets. Inference within each iteration of an
optimization algorithm, for example, requires storing and inverting ΣDTM, which requires O(n2)
space andO(n3) time respectively, where n ,
∑m
i=1 ni is the number of clinical marker observations.
For modern datasets, where n can be in the hundreds of thousands or millions, this is unacceptable.
In this section, we approximate the log-likelihood using techniques from Hensman et al. [2013] that
allows us to apply stochastic variational inference (SVI) [Hoffman et al., 2013].
Recent work in scaling Gaussian processes to large datasets focuses on the idea of inducing
points [Snelson and Ghahramani, 2005, Titsias, 2009], which are a relatively small number of
artificial observations of the Gaussian process that act as a bottleneck and approximately capture
the information contained in the training data. Let f ∈ Rm denote observations of the GP at inputs
{xi}mi=1 and u ∈ Rp denote inducing points at inputs {zi}pi=1. Titsias [2009] constructs the inducing
points as variational parameters by introducing an augmented probability model:
u ∼ N (0,Kpp) , f | u ∼ N (KmpK−1pp u, K˜mm), (6)
where Kpp is the Gram matrix between inducing points, Kmm is the Gram matrix between
observations, Kmp is the cross Gram matrix between observations and inducing points, and
K˜mm , Kmm − KmpK−1pp Kpm. Titsias [2009] then marginalizes over u to construct a low-rank
approximate covariance matrix, which is computationally cheaper to invert using the Woodbury
identity. Hensman et al. [2013] extends these ideas by maintaining a variational distribution over u
that d-separates the observations and satisfies the conditions required to apply SVI [Hoffman et al.,
2013]. Let yf = f +  where  is iid Gaussian noise with variance σ
2, then the key result from
Hensman et al. [2013] that we use here is the following bound:
log p(yf | u) ≥
∑m
i=1 Ep(fi|u)[log p(yfi | fi)]. (7)
In the interest of space, we refer the interested reader to Hensman et al. [2013] for details.
DTM evidence lower bound. When marginalizing over the rows of F, we induced a Gaussian
process over the trajectories, but by doing so we implicitly induced a Gaussian process over the
subject-specific basis coefficients. Let wi , Fxi ∈ Rd denote the curve weights implied by the
mapping F and representation xi, and let w:,k for k ∈ [d] denote the kth coefficient of all subjects
in the dataset. After marginalizing the kth row of F and applying the kernel trick, we see that the
vector of coefficients w:,k has a Gaussian process distribution with mean 0 and covariance function:
Cov(wik, wjk) = αk(xi,xj). Moreover, the Gaussian processes across coefficients are statistically
independent of one another. To lower bound the DTM log-likelihood, we introduce p inducing points
uk for each vector of coefficients w:,k with shared inducing point inputs {zi}pi=1. To refer to all
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inducing points simultaneously, we will use U , [u1, . . . ,ud] and u to denote the “vectorized” form
of U obtained by stacking its columns. Applying the bound in (7) we have:
logp(y | u,x1:m) ≥
m∑
i=1
Ep(wi|u,xi)[log p(yi | wi)]
=
m∑
i=1
logN (yi | µ+ BiU>K−1pp ki, σ2Ini)−
k˜ii
2σ2
Tr[B>i Bi] ,
m∑
i=1
log p˜(yi | u,xi), (8)
where ki , [k(xi, z1), . . . , k(xi, zp)]> and k˜ii is the ith diagonal element of K˜mm. We can then
construct the variational lower bound on log p(y):
log p(y) ≥ Eq(u,x1:m)[log p(y | u,x1:m)]−KL(q(u,x1:m) ‖ p(u,x1:m)) (9)
≥
m∑
i=1
Eq(u,xi)[log p˜(yi | u,xi)]−KL(q(u,x1:m) ‖ p(u,x1:m)), (10)
where we use the lower bound in (8). Finally, to make the lower bound concrete we specify the
variational distribution q(u,x1:m) to be a product of independent multivariate normal distributions:
q(u,x1:M ) , N (u |m,S)
∏m
i=1N (xi |mi,Si), (11)
where the variational parameters to be fit are m, S, and {mi,Si}mi=1.
Stochastic optimization of the lower bound. To apply SVI, we must be able to compute the
gradient of the expected value of log p˜(yi | u,xi) under the variational distributions. Because u and
xi are assumed to be independent in the variational posteriors, we can analyze the expectation in
either order. Fix xi, then we see that log p˜(yi | u,xi) depends on u only through the mean of the
Gaussian density, which is a quadratic term in log likelihood. Because q(u) is multivariate normal,
we can compute the expectation in closed form.
Eq(u)[log p˜(yi | u,xi)] = Eq(U)[logN (yi | µ+ (Bi ⊗ k>i K−1pp )u, σ2Ini)]−
k˜ii
2σ2
Tr[B>i Bi]
= logN (yi | µ+ Cim, σ2Ini)]−
1
2σ2
Tr[SC>i Ci]−
k˜ii
2σ2
Tr[B>i Bi],
where we have defined Ci , (Bi⊗k>i K−1pp ) to be the extended design matrix and⊗ is the Kronecker
product. We now need to compute the expectation of this expression with respect to q(xi), which
entails computing the expectations of ki (a vector) and kik>i (a matrix). In this paper, we assume an
RBF kernel, and so the elements of the vector and matrix are all exponentiated quadratic functions of
xi. This makes the expectations straightforward to compute given that q(xi) is multivariate normal.1
We therefore see that the expected value of log p˜(yi) can be computed in closed form under the
assumed variational distribution.
We use the standard SVI algorithm to optimize the lower bound. We subsample the data, optimize
the likelihood of each example in the batch with respect to the variational parameters over the
representation (mi, Si), and compute approximate gradients of the global variational parameters (m,
S) and the hyperparameters. The likelihood term is conjugate to the prior over u, and so we can
compute the natural gradients with respect to the global variational parameters m and S [Hoffman
et al., 2013, Hensman et al., 2013]. Additional details on the approximate objective and the gradients
required for SVI are given in the supplement. We provide details on initialization, minibatch selection,
and learning rates for our experiments in Section 3.
Inference on new trajectories. The variational distribution over the inducing point values u can
be used to approximate a posterior process over the basis coefficients wi [Hensman et al., 2013].
Therefore, given a representation xi, we have that
wik | xi,m,S ∼ N (k>i K−1ppmk, k˜ii + k>i K−1pp SkkK−1pp ki), (12)
where mk is the approximate posterior mean of the kth column of U and Skk is its covariance. The
approximate joint posterior distribution over all coefficients can be shown to be multivariate normal.
1Other kernels can be used instead, but the expectations may not have closed form expressions.
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Let µ(xi) be the mean of this distribution given representation xi and Σ(xi) be the covariance, then
the posterior predictive distribution over a new trajectory y∗ given the representation x∗ is
y∗ | x∗ ∼ N (µ+ B∗µ(x∗),B∗Σ(x∗)B>∗ + σ2In∗ . (13)
We can then approximately marginalize with respect to the prior over x∗ or a variational approximation
of the posterior given a partial trajectory using a Monte Carlo estimate.
3 Experiments
We now use DTM to analyze clinical marker trajectories of individuals with the autoimmune disease,
scleroderma [Allanore et al., 2015]. Scleroderma is a heterogeneous and complex chronic autoimmune
disease. It can potentially affect many of the visceral organs, such as the heart, lungs, kidneys, and
vasculature. Any given individual may experience only a subset of complications, and the timing of
the symptoms relative to disease onset can vary considerably across individuals. Moreover, there are
no known biomarkers that accurately predict an individual’s disease course. Clinicians and medical
researchers are therefore interested in characterizing and understanding disease progression patterns.
Moreover, there are a number of clinical outcomes responsible for the majority of morbidity among
patients with scleroderma. These include congestive heart failure, pulmonary hypertension and
pulmonary arterial hypertension, gastrointestinal complications, and myositis [Varga et al., 2012].
We use the DTM to study associations between these outcomes and disease trajectories.
We study two scleroderma clinical markers. The first is the percent of predicted forced vital capacity
(PFVC): a pulmonary function test result measuring lung function. PFVC is recorded as percentage
points, and a higher value (near 100) indicates that the individual’s lungs are functioning as expected.
The second clinical marker that we study is the total modified Rodnan skin score (TSS). Scleroderma
is named after its effect on the skin, which becomes hard and fibrous during periods of high disease
activity. Because it is the most clinically apparent symptom, many of the current sub-categorizations
of scleroderma depend on an individual’s pattern of skin disease activity over time [Varga et al.,
2012]. To systematically monitor skin disease activity, clinicians use the TSS which is a quantitative
score between 0 and 55 computed by evaluating skin thickness at 17 sites across the body (higher
scores indicate more active skin disease).
3.1 Experimental Setup
For our experiments, we extract trajectories from one of nation’s largest scleroderma patient registries.
For both PFVC and TSS, we study the trajectory from the time of first symptom until ten years of
follow-up. The PFVC dataset contains trajectories for 2,323 individuals and the TSS dataset contains
2,239 individuals. The median number of observations per individuals is 3 for the PFVC data and 2
for the TSS data. The maximum number of observations is 55 and 22 for PFVC and TSS respectively.
We present two sets of results. In the first, we visualize groups of similar trajectories obtained by
clustering the representations learned by DTM. Although not quantitative, we use these visualizations
as a way to check that the DTM uncovers subpopulations that are consistent with what is currently
known about scleroderma. In the second set of results, we use the learned representations of
trajectories obtained using the LMM, the reduced-rank model (FPCA) as described by James et al.
[2000], and the DTM to statistically test for relationships between important clinical outcomes and
learned disease trajectory representations.
For all experiments and all models, we use a common 5-dimensional B-spline basis composed of
degree-2 polynomials (see e.g. Chapter 20 in Gelman et al. [2014]). We choose knots using the
percentiles of observation times across the entire training set [Ramsay et al., 2002]. For the LMM and
FPCA models, we use EM to fit model parameters. To fit the DTM, we use the LMM estimate to set
the mean µ , noise σ2, and average the diagonal elements of Σ to set the kernel scale α. Length-scales
` are set to 1. For these experiments, we do not learn the hyperparameters during optimization. We
initialize the variational means over xi using the first two unit-scaled principal components of wi
and set the variational covariances to be diagonal with standard deviation 0.1. For both PFVC and
TSS, we use minibatches of size 25 and learn for a total of five epochs (passes over the training data).
The initial learning rate for m and S is 0.1 and decays as t−1 for each epoch t.
3.2 Qualitative Analysis of Representations
The DTM returns approximate posteriors over the representations xi for all individuals in the training
set. We examine these posteriors for both the PFVC and TSS datasets to check for consistency
with what is currently known about scleroderma disease trajectories. In Figure 1 (A) we show
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Figure 1: (A) Groups of PFVC trajectories obtained by hierarchical clustering of DTM representations. (B)
Trajectory representations are color-coded and labeled according to groups shown in (A). Contours reflect
posterior GP over the second B-spline coefficient (blue contours denote smaller values, red denote larger values).
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Figure 2: Same presentation as in Figure 1 but for TSS trajectories.
groups of trajectories uncovered by clustering the learned representations, which are plotted in
Figure 1 (B). Many of the groups shown here align with other work on scleroderma lung disease
subtypes (e.g. Schulam et al. [2015]). In particular, we see rapidly declining trajectories (group [5]),
slowly declining trajectories (group [22]), recovering trajectories (group [23]), and stable trajectories
(group [34]). Surprisingly, we also see a group of individuals who we describe as “late decliners”
(group [28]). These individuals are stable for the first 5-6 years, but begin to decline thereafter. This
is surprising because the onset of scleroderma-related lung disease is currently thought to occur early
in the disease course [Varga et al., 2012]. In Figure 2 (A) we show clusters of TSS trajectories and
the corresponding color-coded representations in Figure 2 (B). These trajectories corroborate what
is currently known about skin disease in scleroderma. In particular, we see individuals who have
minimal activity (e.g. group [1]) and individuals with early activity that later stabilizes (e.g. group
[11]), which correspond to what is known as the limited and diffuse variants of scleroderma [Varga
et al., 2012]. We also find that there are a number of individuals with increasing activity over time
(group [6]) and some whose activity remains high over the ten year period (group [19]). These
patterns are not currently considered to be canonical trajectories and warrant further investigation.
3.3 Associations between Representations and Clinical Outcomes
To quantitatively evaluate the low-dimensional representations learned by the DTM, we statistically
test for relationships between the representations of clinical marker trajectories and important clinical
outcomes. We compare the inferences of the hypothesis test with those made using representations
derived from the LMM and FPCA baselines. For the LMM, we project wi into its 2-dimensional prin-
cipal subspace. For FPCA, we learn a rank-2 covariance, which recovers 2-dimensional embeddings.
To establish that the models are all equally expressive and achieve comparable generalization error, we
present held-out data log-likelihoods in Table 1, which are estimated using 10-fold cross-validation.
We see that the models are roughly equivalent with respect to generalization error.
To test associations between clinical outcomes and learned representations, we use a kernel density
estimator test [Duong et al., 2012] to test the null hypothesis that the distributions across subgroups
with and without the outcome are equivalent. The p-values obtained are listed in Table 2. As a
point of reference, we include two clinical outcomes that should be clearly related to the two clinical
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Table 1: Disease Trajectory Held-out Log-Likelihoods
PFVC TSS
Model Subj. LL Obs. LL Subj. LL Obs. LL
LMM -17.59 (± 1.18) -3.95 (± 0.04) -13.63 (± 1.41) -3.47 (± 0.05)
FPCA -17.89 (± 1.19) -4.03 (± 0.02) -13.76 (± 1.42) -3.47 (± 0.05)
DTM -17.74 (± 1.23) -3.98 (± 0.03) -13.25 (± 1.38) -3.32 (± 0.06)
Table 2: P-values under the null hypothesis that the distributions of trajectory representations are the same
across individuals with and without clinical outcomes. Lower values indicate stronger support for rejection.
PFVC TSS
Outcome LMM FPCA DTM LMM FPCA DTM
Congestive Heart Failure 0.170 0.081 0.013 0.107 0.383 0.189
Pulmonary Hypertension 0.270 ∗0.000 ∗0.000 0.485 0.606 0.564
Pulmonary Arterial Hypertension 0.013 0.020 ∗0.002 0.712 0.808 0.778
Gastrointestinal Complications 0.328 0.073 0.347 0.026 0.035 0.011
Myositis 0.337 ∗0.002 ∗0.004 ∗0.000 ∗0.002 ∗0.000
Interstitial Lung Disease ∗0.000 ∗0.000 ∗0.000 0.553 0.515 0.495
Ulcers and Gangrene 0.410 0.714 0.514 0.573 0.316 ∗0.009
markers. Interstitial lung disease is the most common cause of lung damage in scleroderma [Varga
et al., 2012], and so we confirm that the null hypothesis is rejected for all three models. Similarly,
for TSS we expect ulcers and gangrene to be associated with severe skin disease. In this case, only
the representations learned by DTM reveal this relationship. For the remaining outcomes, we see
that FPCA and DTM reveal similar associations, but that only DTM suggests a relationship with
pulmonary arterial hypertension (PAH). Presence of fibrosis (which drives lung disease progression)
has been shown to be a risk factor in the development of PAH (see Chapter 36 of Varga et al. [2012]),
but only the representations learned by DTM corroborate this finding (see Figure 3).
4 Conclusion
We present the Disease Trajectory Map (DTM), a novel probabilistic model that learns low-
dimensional embeddings of sparse and irregularly sampled clinical time series data. The DTM
is a reformulation of the LMM that places an emphasis on the representations that the model learns.
This view is comparable to that taken by Lawrence [2004] in deriving the Gaussian process latent
variable model (GPLVM) from probabilistic principal component analysis (PPCA) [Tipping and
Bishop, 1999], and indeed the DTM can be interpreted as a “twin kernel” GPLVM (briefly discussed
in the concluding paragraphs) over functional observations. The DTM can also be viewed as an
LMM with a “warped” Gaussian prior over the random effects (see e.g. Damianou et al. [2015]
for a discussion of distributions induced by mapping Gaussian random variables through non-linear
maps). We demonstrate the model by analyzing data extracted from one of the nation’s largest
scleroderma patient registries, and found that the DTM induces structure among trajectories that is
consistent with previous findings and also uncovers several surprising disease trajectory shapes. We
also explore associations between important clinical outcomes and the DTM’s representations and
found statistically significant differences in representations between outcome-defined groups that
were not uncovered by two sets of baseline representations.
(B) FPCA Representations (C) DTM Representations(A) LMM Representations
Figure 3: Scatter plots of representations for the three models color-coded by presence or absence of pulmonary
arterial hypertension (PAH). Groups of trajectories with very few cases of PAH are circled in red.
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A Derivation of Evidence Lower Bound
When marginalizing over the rows of F, we induced a Gaussian process over the trajectories, but by
doing so we implicitly induced a Gaussian process over the subject-specific basis coefficients. Let
wi , Fxi ∈ Rd denote the curve weights implied by the mapping F and representation xi, and let
w:,k for k ∈ [d] denote the kth coefficient of all subjects in the dataset. After marginalizing the kth
row of F and applying the kernel trick, we see that the vector of coefficients w:,k has a Gaussian
process distribution with mean 0 and covariance
Cov(wik, wjk) = αk(xi,xj). (14)
Moreover, the Gaussian processes across coefficients are mutually statistically independent of one
another. To construct our approximate objective, we first approximate each of the d coefficient
Gaussian processes by introducing p inducing points (see e.g. Snelson and Ghahramani [2005],
Titsias [2009]) with values uk ∈ Rp for each k ∈ [d] observed at common inputs zi ∈ Rq for i ∈ [p].
We assume that each w:,k and uk are sampled from a common Gaussian process, which implies the
joint distribution:
uk | θ ∼ N (0,Kpp) (15)
wk | uk,θ ∼ N (KmpK−1pp uk, K˜mm). (16)
where Kpp is the Gram matrix between inducing points, Kmm is the Gram matrix between subjects
(based on their representations xi), Kmp is the cross Gram matrix between subjects and inducing
points, and K˜mm , Kmm −KmpK−1pp Kpm.
Now, we stack the inducing point values u1:d into the columns of a matrix U , [u1, . . . ,ud]. We
will use u to denote the “vectorization” of U obtained by stacking the columns. Each row i of U
can be thought of as the vector of coefficients belonging to a single inducing subject which has an
associated representation zi ∈ Rq . Let y , [y>1 , . . . ,y>m]> be the vector of concatenated trajectories
and W be the matrix containing subject i’s coefficients wi in each row, then following the derivation
of Hensman et al. [2013], we can lower bound the conditional log-probability of y given u and x1:m:
log p(y | u,x1:m) = log
∫
p(y |W)p(W | u,x1:m)dW (17)
= log
∫ m∏
i=1
p(yi | wi)p(W | u,x1:m)dW (18)
≥
∫
p(W | u,x1:m)
m∑
i=1
log p(yi | wi)dW (19)
=
m∑
i=1
Ep(wi|u,xi)[log p(yi | wi)]. (20)
The expectation in each summand is easy to calculate because the mean of yi is linearly dependent
on wi and because the conditional distribution wi given u is multivariate normal. Specifically, we
have that
wi | u,xi ∼ N (U>K−1pp ki, k˜iiId), (21)
where ki is a column vector filled with the ith row of Kmp and k˜ii is the ith diagonal element of K˜mm.
Together with the conditional distribution of yi given wi, we have that each summand can be written
as
Ep(wi|u,xi)[log p(yi | wi)] (22)
= −ni
2
log 2piσ2 − 1
2σ2
Ep(wi|u,xi)[(yi − µ− Biwi)>(yi − µ− Biwi)] (23)
= logN (yi | µ+ BiU>K−1pp ki, σ2Ini)−
k˜ii
2σ2
Tr[B>i Bi] (24)
, log p˜(yi | u,xi). (25)
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We can now write the lower bound on the conditional log-probability as
log p(y | u,x1:m) ≥
m∑
i=1
log p˜(yi | u,xi) , log p˜(y | u,x1:m). (26)
To complete the derivation of the approximate objective, we use the lower bound on log p(y | u,x1:m)
to create a variational lower bound on the marginal log-probability of the trajectories
log p(y) = log
∫
p(y | u,x1:m)p(u,x1:m)du (27)
≥
∫
q(u,x1:m) (log p(y | u,x1:m)− log q(u,x1:m) + log p(u,x1:m)) dudx1:m (28)
≥
∫
q(u,x1:m) (log p˜(y | u,x1:m)− log q(u,x1:m) + log p(u,x1:m)) dudx1:m (29)
, log p˜(y). (30)
We assume that u, x1, . . . ,xm are all mutually independent in the variational posterior. We use a
multivariate normal variational approximation for each xi with variational parameters mi and Si.
Fixing xi, to find the the optimal form for q(u), note that each log p˜(yi | u,xi) is composed of a
log-likelihood plus an additive term that is independent of u. Therefore, the terms that depend on u
can be written as:
Eq(u)
[
m∑
i=1
logN (yi | µ+ BiU>K−1pp ki, σ2Ini)
]
−KL(q‖p). (31)
Now, note that the mean in any of the log-likelihood terms can be rewritten as
µ+ BiU
>K−1pp ki = µ+ (Bi ⊗ k>i K−1pp )u, (32)
Let Ci , (Bi ⊗ k>i K−1pp ) denote the extended design matrix obtained through this rewriting, and
recall that each column uk is normally distributed with mean zero and covariance Kpp. The prior over
the vectorized matrix u is therefore also multivariate normal. The expression above is maximized
when q(u) is equal to the posterior over u given the observed trajectories. Because the prior is
multivariate normal and the mean of the likelihood depends linearly on u, the posterior must also be
multivariate normal. Moreover, we know its exact form:
m∗ = S∗
(
σ−2
m∑
i=1
C>i (yi − µ)
)
, S∗ =
(
σ−2
m∑
i=1
C>i Ci + (Id ⊗K−1pp )
)−1
. (33)
We therefore parameterize q(u) as a multivariate normal distribution with variational parameters m
and S.
We now derive a closed-form expression for the expectation of log p˜(yi | u,xi) under variational
posterior distribution. Because u and xi are assumed to be independent in the variational posteriors,
we can analyze the expectation in either order. Fix xi, then we see that log p˜(yi | u,xi) depends
on u only through the mean of the Gaussian density, which is a quadratic term in log likelihood.
Because q(u) is multivariate normal, we can compute the expectation in closed form.
Eq(u)[log p˜(yi | u,xi)] = Eq(U)[logN (yi | µ+ (Bi ⊗ k>i K−1pp )u, σ2Ini)]−
k˜ii
2σ2
Tr[B>i Bi]
= logN (yi | µ+ Cim, σ2Ini)]−
1
2σ2
Tr[SC>i Ci]−
k˜ii
2σ2
Tr[B>i Bi],
We can compute the expectation of Eq(u)[log p˜(yi | u,xi)] in closed form by noting that we need
only compute expectations of ki and kik>i . Specifically, we have that
Eq(xi)[k(xi, zj)] =
α
|Si|1/2|A|1/2 exp
{
1
2
(B>A−1b− c)
}
, (34)
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where A = S−1i + `
−2Iq, b = S−1i mi + `
−2zj , and c = m>i S
−1
i m+ `
−2z>j zj . Similarly, for the
expected outer product, we have
Eq(xi)[k(xi, zj)k(xi, zk)] =
α
|Si|1/2|A|1/2 exp
{
1
2
(B>A−1b− c)
}
, (35)
where A = S−1i +2`
−2Iq , b = S−1i mi+`
−2zj +`−2zk, and c = m>i S
−1
i m+`
−2z>j zj +`
−2z>k zk.
Importantly, we can simply substitute these expectations into Eq(u)[log p˜(yi | u,xi)] and the form of
the lower bound does not change (it is still a Gaussian log-likelihood plus the additional trace terms).
B Optimizing the Evidence Lower Bound
To formulate the complete objective, we use the lower bound derived above and place priors on
the observation noise σ2, and the hyperparameters of the kernel k(·, ·). In this section and in our
experiments we assume that the kernel is a radial basis function (RBF) with scale α and length-scale
(or bandwidth) `. We assumelog normal distributions over σ2, α, and ` with mean parameters ms,
ma, m` respectively and precision parameters ρs, ρa, and ρ` respectively. Our objective is therefore
JSA-DTM(m,S,m1:m,S1:m, µ, σ2, α, `) = (36)
m∑
i=1
−ni
2
log 2piσ2 − 1
2σ2
Eq(xi)[‖yi − µ− (Bi ⊗ k>i K−1pp )m‖22] (37)
+
m∑
i=1
− 1
2σ2
Tr[S(B>i Bi ⊗K−1pp Eq(xi)[kik>i ]K−1pp )] (38)
+
m∑
i=1
− 1
2σ2
Tr[B>i Bi](α− Eq(xi)[k>i K−1pp ki]) (39)
−
m∑
i=1
1
2
(
Tr[Si +mim
>
i ]− q − log |Si|
)
(40)
− 1
2
(
Tr[(S +mm>)(Id ⊗K−1pp )]− pd+ log
|Kpp|d
|S|
)
(41)
− ρs
2
‖ log σ2 −ms‖22 −
ρa
2
‖ logα−ma‖22 −
ρ`
2
‖ log `−m`‖22. (42)
Note that the last three lines above can be seen as regularizers (log priors for the hyperparameters and
a KL divergence between the variational distribution q and the prior p). The first four lines can be
decomposed across subjects, suggesting that we can use stochastic approximation of the objective
and its gradients to derive a scalable algorithm for optimizing the objective.
We define an iterative first-order optimization algorithm. In broad strokes, within each iteration we
will sample a single subject i (or a batch of patients), maximize the objective with respect to mi and
Si while holding the global variables fixed, compute the approximate gradients of the objective, and
take a small step in the direction of each gradient for each parameter (the step size is determined by
a learning schedule, which may be specific to each global variable). We discuss each step in detail
below. We do so assuming a single sampled subject i, although in principle we can sample a batch of
subjects to reduce variance in the gradient estimate.
Maximizing wrt local variables (mi,Si). Before computing gradients of the approximate objec-
tive with respect to the global parameters, we first do a block coordinate optimization over the local
variational parameters of subject i. We optimize:
Ji(xi) = (43)
− ni
2
log 2piσ2 − 1
2σ2
Eq(xi)[‖yi − µ− (Bi ⊗ k>i K−1pp )m‖22] (44)
− 1
2σ2
Tr[S(B>i Bi ⊗K−1pp Eq(xi)[kik>i ]K−1pp )] (45)
− 1
2σ2
Tr[B>i Bi](α− Eq(xi)[k>i K−1pp ki]). (46)
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We can optimize this expression using a gradient-based optimizer. We use the scaled conjugate
gradients algorithm.
Estimating gradients of global variables. Having sampled subject i and refit her local variational
parameters, we now want to approximate the gradient of the full objective with respect to the global
variables m, S, µ, σ2, α, and `. We first look at the approximate gradient with respect to m.
∇ˆJSA-DTM(m) = Eq(xi)[
m
σ2
(B>i ⊗K−1pp ki)(yi − µ− (B⊗ k>i K−1pp )m)]− (Id ⊗K−1pp )m. (47)
The approximate gradient with respect to S is
∇ˆJSA-DTM(S) =−
m
2σ2
Tr[(B>i Bi ⊗K−1pp Eq(xi)[kik>i ]K−1pp )] (48)
− 1
2
Tr[(Id ⊗K−1pp )] +
1
2
Tr[S−1]. (49)
Note that if we set these approximate gradients to 0, we obtain the following estimates of m and S:
mˆ = Sˆ
(m
σ2
(B>i ⊗K−1pp Eq(xi)[ki])(y − µ)
)
(50)
Sˆ =
(m
σ2
(B>i Bi ⊗K−1pp Eq(xi)[kik>i ]K−1pp ) + (Id ⊗K−1pp )
)−1
(51)
We can improve the rate of convergence of our algorithm by taking the geometry of the space of
distributions parameterized by m and S into account. We do so by using the natural gradients
for these two parameters instead of the approximations above. Let θ1 and θ2 denote the canonical
parameterization of the variational multivariate normal, then the gradient updates at time t are
Hoffman et al. [2013]:
θt1 = θ
t−1
1 + λt(η
t−1
1 − θt−11 ) (52)
θt2 = θ
t−1
2 + λt(η
t−1
2 − θt−12 ), (53)
where
ηt−11 =
m
σ2
(B>i ⊗K−1pp Eq(xi)[ki])(y − µ) (54)
ηt−12 = −
m
2σ2
(B>i Bi ⊗K−1pp Eq(xi)[kik>i ]K−1pp ) (55)
To update the hyperparamters, we need to compute the gradients with respect to µ, σ2, α, and `.
We parameterize σ2, α, and ` using their logarithms, and so present gradients with respect to that
representation. To make the expressions more clear, we present the gradients as differentials with
respect to the kernel, which can be completed using the chain rule. The estimate of the gradient with
respect to µ is
∇ˆJSA-DTM(µ) =
m
σ2
(yi − µ− (Bi ⊗ Eq(xi)[k>i ]K−1pp )m)>1ni . (56)
The estimate of the gradient with respect to log σ2 is
∇ˆJSA-DTM(log σ2) =−
mni
2
+
m
2σ2
Eq(xi)[‖yi − µ− (Bi ⊗ k>i K−1pp )m‖22] (57)
+
m
2σ2
Tr[S(B>i Bi ⊗K−1pp Eq(xi)[kix>i ]K−1pp )] (58)
+
m
2σ2
Tr[B>i B](α− Tr[K−1pp Eq(xi)[kix>i ]]) (59)
− ρs(log σ2 −ms). (60)
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The estimate of the gradient with respect to logα is
∇ˆSA-DTM(logα) = (61)
m
σ2
Eq(xi)[(yi − µ− Cm)>(Bi ⊗ ∂k>i K−1pp − k>i K−1pp ∂KppK−1pp )m] (62)
− m
σ2
Eq(xi)[Tr[SC
>
i (Bi ⊗ ∂k>i K−1pp − k>i K−1pp ∂KppK−1pp )]] (63)
− m
2σ2
Tr[B>i Bi]α (64)
+
m
2σ2
Tr[B>i Bi](2Eq(xi)[k
>
i ]K
−1
pp ∂Eq(xi)[ki]− Tr[K−1pp ∂KppK−1pp Eq(xi)[kix>i ]]) (65)
+
1
2
(
Tr[(S + mm>)(Id ⊗K−1pp ∂KppK−1pp )]− dTr[K−1pp ∂Kpp]
)
. (66)
The estimate of the gradient with respect to log ` is
∇ˆSA-DTM(log `) = (67)
m
σ2
Eq(xi)[(yi − µ− Cm)>(Bi ⊗ ∂k>i K−1pp − k>i K−1pp ∂KppK−1pp )m] (68)
− m
σ2
Eq(xi)[Tr[SC
>
i (Bi ⊗ ∂k>i K−1pp − k>i K−1pp ∂KppK−1pp )]] (69)
+
m
2σ2
Tr[B>i Bi](2Eq(xi)[k
>
i ]K
−1
pp ∂Eq(xi)[ki]− Tr[K−1pp ∂KppK−1pp Eq(xi)[kix>i ]]) (70)
+
1
2
(
Tr[(S + mm>)(Id ⊗K−1pp ∂KppK−1pp )]− dTr[K−1pp ∂Kpp]
)
. (71)
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